<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2019.91006</article-id><article-id pub-id-type="publisher-id">WJCR-28370</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20190100000_55721250.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  紫杉醇脂质体与多西他赛联合顺铂治疗晚期肺鳞癌的疗效与安全性对比
  Comparison of Paclitaxel Liposome Combined with Cisplatin and Docetaxel Combined with Cisplatin in the Treatment of Advanced Lung Squamous Cell Carcinoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>莹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>其森</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>初峰</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>山东省肿瘤医院，山东 济南济南大学山东省医学科学院医学与生命科学学院，山东 济南</addr-line></aff><aff id="aff2"><addr-line>山东省胸科医院肺功能室，山东 济南</addr-line></aff><aff id="aff4"><addr-line>山东省肿瘤医院呼吸肿瘤内科，山东 济南</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>24</day><month>12</month><year>2018</year></pub-date><volume>09</volume><issue>01</issue><fpage>32</fpage><lpage>38</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨注射用紫杉醇脂质体联合顺铂与多西他赛联合顺铂一线治疗晚期肺鳞癌的疗效和不良反应。方法：搜集并筛选2010年7月至2016年7月在山东省肿瘤医院确诊为晚期肺鳞癌并接受注射用紫杉醇脂质体联合顺铂(LP组)或多西他赛联合顺铂(DP组)一线化疗方案的病例，回顾分析两者的疗效和不良反应。结果：共纳入200例患者(各组100例)，LP组和DP组的有效率分别为39.0%和37.0% (P = 0.771)，疾病控制率分别为88.0%和85.0% (P = 0.415)，中位无进展生存期分别为5.6个月和5.2个月(P = 0.985)，中位总生存期分别为14.1个月和14.9个月(P = 0.0.713)。药物不良反应相比，LP组在骨髓抑制、胃肠道反应及过敏反应方面较轻(均P &lt; 0.05)。结论：LP和DP两种方案治疗晚期肺鳞癌的疗效相似，但LP方案在骨髓抑制、胃肠道反应、过敏反应等方面的不良反应较轻。
    Objective: To explore the clinical efficacy and adverse reactions of paclitaxel liposome combined with cisplatin and docetaxel in combination with cisplatin in the treatment of patients with ad-vanced lung squamous cell carcinoma. Methods: To collect and select cases of patients with ad-vanced lung squamous cell carcinoma who were admitted to Shandong Provincial Cancer Hospital and from July 2010 to July 2016, and received paclitaxel liposome combined with cisplatin (LP group) or docetaxel in combination with cisplatin (DP group), and their efficacy and adverse reac-tions were compared. Results: A total of 200 patients (100 patients in each group) were included. The effective rates of the LP group and the DP group were 39.0% and 37.0% (P = 0.771), the disease control rates were 88.0% and 85.0% (P = 0.415), the median progression-free survival was 5.6 months and 5.2 months (P = 0.985) and the median overall survival was 14.1 months and 14.9 months (P = 0.713). Compared with the adverse reactions in the DP group, the LP group was lighter in myelosuppression, gastrointestinal reactions and allergic reaction (all P &lt; 0.05). Conclusion: The efficacy of the LP regimen in the treatment of advanced lung squamous cell carcinoma is similar to that of the DP regimen, but the LP regimen has less adverse reactions in myelosuppression, gastrointestinal reactions and allergic reaction. 
  
 
</p></abstract><kwd-group><kwd>紫杉醇脂质体，多西他赛，顺铂，晚期肺鳞状细胞癌，临床有效率，不良反应, Paclitaxel Liposome</kwd><kwd> Docetaxel</kwd><kwd> Cisplatin</kwd><kwd> Advanced Lung Squamous Cell Carcinoma</kwd><kwd> 
Clinical Efficiency</kwd><kwd> Adverse Reactions</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>紫杉醇脂质体与多西他赛联合顺铂治疗晚期肺鳞癌的疗效与安全性对比<sup> </sup></title><p>张莹<sup>1,2,3</sup>，郭其森<sup>1,2*</sup>，张初峰<sup>2</sup></p><p><sup>1</sup>济南大学山东省医学科学院医学与生命科学学院，山东 济南</p><p><sup>2</sup>山东省肿瘤医院呼吸肿瘤内科，山东 济南</p><p><sup>3</sup>山东省胸科医院肺功能室，山东 济南</p><disp-formula id="hanspub.28370-formula10"><graphic xlink:href="//html.hanspub.org/file/6-2150166x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年12月13日；录用日期：2019年1月1日；发布日期：2019年1月8日</p><disp-formula id="hanspub.28370-formula11"><graphic xlink:href="//html.hanspub.org/file/6-2150166x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨注射用紫杉醇脂质体联合顺铂与多西他赛联合顺铂一线治疗晚期肺鳞癌的疗效和不良反应。方法：搜集并筛选2010年7月至2016年7月在山东省肿瘤医院确诊为晚期肺鳞癌并接受注射用紫杉醇脂质体联合顺铂(LP组)或多西他赛联合顺铂(DP组)一线化疗方案的病例，回顾分析两者的疗效和不良反应。结果：共纳入200例患者(各组100例)，LP组和DP组的有效率分别为39.0%和37.0% (P = 0.771)，疾病控制率分别为88.0%和85.0% (P = 0.415)，中位无进展生存期分别为5.6个月和5.2个月(P = 0.985)，中位总生存期分别为14.1个月和14.9个月(P = 0.0.713)。药物不良反应相比，LP组在骨髓抑制、胃肠道反应及过敏反应方面较轻(均P &lt; 0.05)。结论：LP和DP两种方案治疗晚期肺鳞癌的疗效相似，但LP方案在骨髓抑制、胃肠道反应、过敏反应等方面的不良反应较轻。</p><p>关键词 :紫杉醇脂质体，多西他赛，顺铂，晚期肺鳞状细胞癌，临床有效率，不良反应</p><disp-formula id="hanspub.28370-formula12"><graphic xlink:href="//html.hanspub.org/file/6-2150166x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/6-2150166x8_hanspub.png" /> <img src="//html.hanspub.org/file/6-2150166x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>在我国肺癌发病率(53.57/100,000)及死亡率(45.57/100,000)分别位居恶性肿瘤发病率及死亡率的第1位 [<xref ref-type="bibr" rid="hanspub.28370-ref1">1</xref>] 。但因早期诊断技术的局限性及缺乏早期特异性临床表现，临床上约70%的患者确诊时已是中晚期，错过了手术时机 [<xref ref-type="bibr" rid="hanspub.28370-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.28370-ref3">3</xref>] 。多项研究表明以铂类为主的联合方案(紫杉醇，吉西他滨，多西他赛，长春瑞滨)已经成为晚期非小细胞肺癌一线化疗的标准治疗方案 [<xref ref-type="bibr" rid="hanspub.28370-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.28370-ref5">5</xref>] 。多西他赛是半合成紫杉醇类似物，对于非小细胞肺癌有较好疗效 [<xref ref-type="bibr" rid="hanspub.28370-ref8">8</xref>] 。多西他赛联合铂类方案是FDA批准的一线治疗局部晚期或转移性非小细胞肺癌药物 [<xref ref-type="bibr" rid="hanspub.28370-ref9">9</xref>] 。注射用紫杉醇脂质体(力扑素)通过脂质体替代聚氧乙烯蓖麻油以及无水乙醇复合溶媒，不仅降低了紫杉醇毒性，还减少了溶媒导致的过敏反应 [<xref ref-type="bibr" rid="hanspub.28370-ref10">10</xref>] 。本研究通过对临床资料的回顾性分析，探讨紫杉醇脂质体联合顺铂对照多西他赛联合顺铂治疗晚期肺鳞状细胞癌的疗效及安全性。</p></sec><sec id="s4"><title>2. 资料与方法</title><p>1) 临床资料，搜集并筛选2010年7月到2016年7月在山东省肿瘤医院(本研究已获得山东省肿瘤医院伦理委员会许可)确诊为晚期肺鳞癌并接受了LP或者DP一线化疗方案的病例，分别分为LP组和DP组，回顾性对比分析两者的中位无进展生存期，中位总生存期和药物不良反应。</p><p>2) 病例入选标准：a) 男女不限，年龄18~75周岁；b) 入院时ECOG体力状况(PS)评分：0~2分；c) 通过病理诊断为肺鳞状细胞癌，且TNM分期为IV期；d) 临床和影像学检查结果提示无法行手术根治治疗；影像学检查至少有1处可测量的病灶；e) 心电图检查、血液学及肝肾功能检测基本正常；f) 接受LP方案或DP方案一线化疗治疗，满2个周期的患者，分别纳入LP组和DP组。</p><p>3) 病例排除标准：a) 因对试验药物过敏或其他原因，未完成2个周期化疗者；b) 合用研究方案外的抗肿瘤药物者，或者接受其他生物或免疫疗法的患者；c) 病历资料不完整者以及失访者。</p><p>4) 研究方法和研究指标严格完整地收集和纳入接受LP或DP方案一线治疗晚期肺鳞癌的病例，分为LP组和DP组研究随访所得数据，应用统计学工具SPSS 18.0对收集的结果进行分析对比两组的有效率、中位数无进展生存期、中位数总生存期和药物不良反应等指标。</p><p>a)有效率，根据美国国家癌症研究所实体瘤疗效评价标准(NCI RECIST) [<xref ref-type="bibr" rid="hanspub.28370-ref6">6</xref>] 治疗效果分为：完全缓解(CR)、部分缓解(PR)、稳定(SD)、进展(PD)。有效率(RR) = (CR + PR)/总例数 * 100%，疾病控制率(DCR) = (CR + PR + SD)/总例数 * 100%。</p><p>b) 无进展生存期(Progression-Free-Survival, PFS)：为化疗开始起到病人出现肿瘤进展或死亡的时间 [<xref ref-type="bibr" rid="hanspub.28370-ref7">7</xref>] 。</p><p>c) 总生存期(Overall survival, OS)：化疗开始至因任何原因引起死亡的时间。</p><p>d) 药物不良反应，美国国家癌症研究所常见不良事件评价标准(NCI CTCAE)对不良反应进行观察和判断，分为I~IV度 [<xref ref-type="bibr" rid="hanspub.28370-ref8">8</xref>]，并进行对比。</p></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. LP组与DP组的基本条件比较</title><p>纳入研究的患者中，在性别、年龄、吸烟史以及ECOG的PS评分等基本资料等方面，LP组与DP组患者之间差异均无统计学意义(即均P &gt; 0.05)，故本此研究的纳入对象具有可比性(表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of patient basic data between LP group and DP grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >LP组</th><th align="center" valign="middle" >DP组</th><th align="center" valign="middle" >x<sup> 2</sup>值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >77</td><td align="center" valign="middle"  rowspan="2"  >0.658</td><td align="center" valign="middle"  rowspan="2"  >0.417</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >23</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤65</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >33</td><td align="center" valign="middle"  rowspan="2"  >0.781</td><td align="center" valign="middle"  rowspan="2"  >0.377</td></tr><tr><td align="center" valign="middle" >&gt;65</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" >67</td></tr><tr><td align="center" valign="middle" >吸烟史</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >80</td><td align="center" valign="middle"  rowspan="2"  >0.121</td><td align="center" valign="middle"  rowspan="2"  >0.728</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >20</td></tr><tr><td align="center" valign="middle" >PS评分</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >0~1</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >71</td><td align="center" valign="middle"  rowspan="2"  >0.226</td><td align="center" valign="middle"  rowspan="2"  >0.635</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >29</td></tr></tbody></table></table-wrap><p>表1. LP组与DP组患者基本资料比较</p></sec><sec id="s5_2"><title>3.2. LP组与DP组的临床疗效对比</title><p>对比临床疗效，LP组中PR 39例，SD 49例，PD 12例，RR为39.0%，DCR为88%；而DP组中PR 37例，SD 47例，PD 16例，RR为37.0%，DCR为84%；比较两组的RR、DCR，差异无统计学意义(P &gt; 0.05)，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of the clinical efficacy between LP group and DP grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >总数</th><th align="center" valign="middle" >CR</th><th align="center" valign="middle" >PR</th><th align="center" valign="middle" >SD</th><th align="center" valign="middle" >PD</th><th align="center" valign="middle" >RR</th><th align="center" valign="middle" >DCR</th></tr></thead><tr><td align="center" valign="middle" >LP组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >39%</td><td align="center" valign="middle" >88%</td></tr><tr><td align="center" valign="middle" >DP组</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >37%</td><td align="center" valign="middle" >85%</td></tr><tr><td align="center" valign="middle" >x<sup> 2</sup>值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.085</td><td align="center" valign="middle" >0.385</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.771</td><td align="center" valign="middle" >0.535</td></tr></tbody></table></table-wrap><p>表2. LP组与DP组患者临床疗效比较</p></sec><sec id="s5_3"><title>3.3. LP组与DP组的药物不良反应比较</title><p>对比药物不良反应在两组中的发生情况，在骨髓抑制、消化道反应方面、过敏反应等的不良反应方面，DP组较LP组更明显，包括白细胞减少、胃肠道反应和皮疹等方面都有统计学差异(均P &lt; 0.05)。而在血小板减少、血红蛋白减少、肝功能损害、肾功能损害和周围神经毒性等方面，两者的发生率差别无统计学意义(均P &gt; 0.05)，见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of the adverse reactions between LP group and DP grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >毒副作用</th><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="2"  >分级</th><th align="center" valign="middle"  rowspan="2"  >总发生率</th><th align="center" valign="middle"  rowspan="2"  >x<sup>2</sup>值</th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >Ⅰ+Ⅱ</td><td align="center" valign="middle" >Ⅲ+Ⅳ</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >WBC减少</td><td align="center" valign="middle" >LP</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >43</td><td align="center" valign="middle"  rowspan="2"  >7.546</td><td align="center" valign="middle"  rowspan="2"  >0.023</td></tr><tr><td align="center" valign="middle" >DP</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >62</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >贫血</td><td align="center" valign="middle" >LP</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >11</td><td align="center" valign="middle"  rowspan="2"  >3.783</td><td align="center" valign="middle"  rowspan="2"  >0.154</td></tr><tr><td align="center" valign="middle" >DP</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >21</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >PLT减少</td><td align="center" valign="middle" >LP</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >13</td><td align="center" valign="middle"  rowspan="2"  >5.433</td><td align="center" valign="middle"  rowspan="2"  >0.066</td></tr><tr><td align="center" valign="middle" >DP</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >26</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >消化反应</td><td align="center" valign="middle" >LP</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >69</td><td align="center" valign="middle"  rowspan="2"  >9.457</td><td align="center" valign="middle"  rowspan="2"  >0.009</td></tr><tr><td align="center" valign="middle" >DP</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >87</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >肝功能</td><td align="center" valign="middle" >LP</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >24</td><td align="center" valign="middle"  rowspan="2"  >0.241</td><td align="center" valign="middle"  rowspan="2"  >0.886</td></tr><tr><td align="center" valign="middle" >DP</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >25</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >肾功能</td><td align="center" valign="middle" >LP</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >18</td><td align="center" valign="middle"  rowspan="2"  >0.310</td><td align="center" valign="middle"  rowspan="2"  >0.856</td></tr><tr><td align="center" valign="middle" >DP</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >20</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >皮疹</td><td align="center" valign="middle" >LP</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >9</td><td align="center" valign="middle"  rowspan="2"  >6.818</td><td align="center" valign="middle"  rowspan="2"  >0.033</td></tr><tr><td align="center" valign="middle" >DP</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >22</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >NS毒性</td><td align="center" valign="middle" >LP</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >15</td><td align="center" valign="middle"  rowspan="2"  >0.682</td><td align="center" valign="middle"  rowspan="2"  >0.711</td></tr><tr><td align="center" valign="middle" >DP</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >15</td></tr></tbody></table></table-wrap><p>表3. LP组与DP组的药物不良反应比较</p></sec><sec id="s5_4"><title>3.4. LP组与DP组的生存期比较</title><p>LP组的中位数无进展生存期为5.6个月，中位数总生存期为14.1个月；DP组的中位数无进展生存期为5.2个月，中位数总生存期为14.9个月。LP组和DP组的无进展生存期(x<sup>2</sup> = 0.003, P = 0.985)和总生存期(x<sup>2</sup> = 0.135, P = 0.713)比较，其差异均无统计学意义(均P &gt; 0.05) (见图1、图2)。</p><p>图1. LP组与DP组的无进展生存期比较</p><p>图2. LP组与DP组的总生存期比较</p><p>综上所述，LP和DP两种方案治疗治疗晚期肺鳞癌的有效率和疾病控制率相似，但LP方案在骨髓抑制、胃肠道反应、过敏反应等方面的不良反应较DP组明显减小。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>肺癌现已成为全球癌症相关性死亡的重要病因，也是我国发病率和死亡率最高的恶性肿瘤 [<xref ref-type="bibr" rid="hanspub.28370-ref1">1</xref>] 。但因其具有发病隐匿、症状缺乏特异性等特点，导致患者确诊时已进展为中晚期，错失了最佳的手术治疗时机，只能通过化疗等方式控制病情。目前临床上作为治疗中晚期NSCLC的一线治疗方案多采用长春瑞滨、紫杉醇、吉西他滨等三代化疗药物联合顺铂化疗，对于延长患者生存期、改善患者生存质量等方面有较明显效果 [<xref ref-type="bibr" rid="hanspub.28370-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.28370-ref5">5</xref>] 。</p><p>美国国立综合癌症网络(NCCN)指南中推荐紫杉醇联合铂类治疗晚期NSCLC，有效率为24%~46% [<xref ref-type="bibr" rid="hanspub.28370-ref10">10</xref>] 。紫杉醇为细胞毒性抗肿瘤药物，通过促进微管双聚体装配、阻止微管双聚体解聚、影响整个细胞周期微管的排列、导致细胞分裂期内微管形状体形成等方式来阻碍细胞分裂，达到抑癌效果 [<xref ref-type="bibr" rid="hanspub.28370-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.28370-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.28370-ref13">13</xref>] 。但普通紫杉醇因水溶性低，需要溶解于无水乙醇和聚氧乙基代蓖麻油组成的溶媒内使用，既影响药效，又易出现神经末梢毒性、过敏反应等不良反应 [<xref ref-type="bibr" rid="hanspub.28370-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.28370-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.28370-ref15">15</xref>] 。多西他赛是一种半合成紫杉醇类似物，具有较高的抗癌活性，在体外人瘤株筛选和动物试验中对多种肿瘤均有效，属于广谱的抗肿瘤植物药，目前已在北美和欧盟国家被用作治疗晚期乳腺癌和非小细胞肺癌的一线用药 [<xref ref-type="bibr" rid="hanspub.28370-ref9">9</xref>] 。然而，多西他赛水溶性仍较低，且在体内呈非选择性分布、半衰期短，使其临床应用也受到一定限制 [<xref ref-type="bibr" rid="hanspub.28370-ref13">13</xref>] 。随着药物研究的发展，脂质体作为一种新型药物载体，延长了药物半衰期，提高了药物靶向作用，并减少了药物不良反应，为中晚期NSCLC的治疗带来了新的治疗方案 [<xref ref-type="bibr" rid="hanspub.28370-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.28370-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.28370-ref17">17</xref>] 。陈强等的研究 [<xref ref-type="bibr" rid="hanspub.28370-ref18">18</xref>] 提示：与紫杉醇联合顺铂相比，紫杉醇脂质体联合顺铂治疗NSCLC的疗效无明显差别，但不良反应明显减轻。</p><p>本研究对比观察了LP和DP两种化疗方案治疗晚期肺鳞状细胞癌的疗效和安全性。发现两组疗效相似：在RR、DCR、无进展生存期及总生存期等方面相比较，差异无统计学意义(均P &gt; 0.05)。而在不良反应方面，LP方案在骨髓抑制(包括白细胞减少)、胃肠道反应及过敏反应(包括皮疹)等方面的不良反应较轻，差异有统计学意义(P &lt; 0.05)。</p><p>总之，本研究初步证实，对于晚期肺鳞状细胞癌化疗，紫杉醇脂质体疗效与多西他赛相近，但在骨髓抑制(包括白细胞减少)、胃肠道反应及过敏反应(包括皮疹)等不良反应方面，紫杉醇脂质体明显好于多西他赛。因此，对于高龄、基础疾病多、体力状况差等的晚期肺鳞状细胞癌患者，可以考虑应用紫杉醇脂质体联合顺铂方案以提高患者对化疗的耐受，进而完成系统化疗，改善预后，提高患者生活质量。因本研究为单中心、回顾性研究，且病例数有限，其结果尚需更大样本量、多中心、前瞻性、随机对照的研究来进一步验证。</p></sec><sec id="s7"><title>文章引用</title><p>张 莹,郭其森,张初峰. 紫杉醇脂质体与多西他赛联合顺铂治疗晚期肺鳞癌的疗效与安全性对比 Comparison of Paclitaxel Liposome Combined with Cisplatin and Docetaxel Combined with Cisplatin in the Treatment of Advanced Lung Squamous Cell Carcinoma[J]. 世界肿瘤研究, 2019, 09(01): 32-38. https://doi.org/10.12677/WJCR.2019.91006</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.28370-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">赫捷, 陈万青. 国家癌症中心和卫生部疾病预防与控制局. 中国癌症登记年报2012 [M]. 北京: 军事医学科学出版社, 2012.</mixed-citation></ref><ref id="hanspub.28370-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">曾晓梅, 李之曦, 侯梅. 紫杉醇脂质体单药与紫杉醇脂质体联合奥沙利铂一线治疗老年晚期非小细胞肺癌的随机对照研究[J]. 中国肺癌杂志, 2012, 15(2): 84-89.</mixed-citation></ref><ref id="hanspub.28370-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">杨静翔, 罗虎, 周向东. 紫杉醇脂质体对比吉西他滨联合顺铂一线治疗中晚期肺鳞癌的疗效评价[J]. 第三军医大学学报, 2014, 36(2): 140-143.</mixed-citation></ref><ref id="hanspub.28370-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">罗虎, 杨静翔, 宫亮, 等. 紫杉醇脂质体联合顺铂对比吉西他滨联合顺铂一线治疗伴有区域淋巴结转移的晚期非小细胞肺癌的临床研究[J]. 中国癌症杂志, 2013, 23(12): 995-1000.</mixed-citation></ref><ref id="hanspub.28370-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Joo, J.H., Song, S.Y., Kim, S.S., et al. (2015) Definitive Radiotherapy Alone over 60 Gy for Patients Unfit for Com-bined Treatment to Stage II-III Non-Small Cell Lung Cancer: Retrospective Analysis. Radiation Oncology, 10, 250.  
https://doi.org/10.1186/s13014-015-0560-z</mixed-citation></ref><ref id="hanspub.28370-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247.  
https://doi.org/10.1016/j.ejca.2008.10.026</mixed-citation></ref><ref id="hanspub.28370-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">管忠震, 张力, 李龙芸, 等. 吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究[J]. 癌症, 2005, 24(8): 980-984.</mixed-citation></ref><ref id="hanspub.28370-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Cavaletti, G., Frigeni, B., Lanzani, F., et al. (2007) The Total Neuropathy Score as an Assessment Tool for Grading the Course of Chemotherapy-Induced Peripheral Neurotoxicity: Comparison with the National Cancer Institute-Common Toxicity Scale. Journal of the Peripheral Nervous System, 12, 210-215.  
https://doi.org/10.1111/j.1529-8027.2007.00141.x</mixed-citation></ref><ref id="hanspub.28370-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">潘锋君, 田伟强, 吴小芬, 等. 多西他赛对比吉西他滨联合顺铂方案治疗非小细胞肺癌临床疗效[J]. 中国临床药理学杂志, 2014, 30(10): 949-951.</mixed-citation></ref><ref id="hanspub.28370-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">刘继柱, 徐文喜, 王斌. 多西他赛联合洛铂或顺铂治疗晚期非小细胞肺癌的临床研究[J]. 临床肺科杂志, 2014, 19(10): 1852-1853.</mixed-citation></ref><ref id="hanspub.28370-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lu, B., Sun, L., Yan, X., Ai, Z., et al. (2015) Intratumoral Chemotherapy with Paclitaxel Liposome Combined with Systemic Chemotherapy: A New Method of Ne-oadjuvant Chemotherapy for Stage III Unresectable Non-Small Cell Lung Cancer. Medical Oncology, 32, 345. https://doi.org/10.1007/s12032-014-0345-5</mixed-citation></ref><ref id="hanspub.28370-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Huang, S.T., Wang, Y.P., Chen, Y.H., et al. (2018) Liposomal Paclitaxel In-duces Fewer Hematopoietic and Cardiovascular Complications than Bioequivalent Doses of Taxol. International Journal of Oncology, 1105-1117.  
https://doi.org/10.3892/ijo.2018.4449</mixed-citation></ref><ref id="hanspub.28370-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">张丹华, 周恩相. 紫杉醇注射液、紫杉醇脂质体以及多西他赛治疗乳腺癌的疗效及安全性[J]. 中国癌症杂志, 2013, 23(12): 1014-1016.</mixed-citation></ref><ref id="hanspub.28370-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ju, R.J., Cheng, L., Xiao, Y., et al. (2018) PTD Modified Paclitaxel Anti-Resistant Liposomes for Treatment of Drug-Resistant Non-Small Cell Lung Cancer. Journal of Liposome Research, 28, 236-248.  
https://doi.org/10.1080/08982104.2017.1327542</mixed-citation></ref><ref id="hanspub.28370-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Bernabeu, E., Cagel, M., Lagomarsino, E., et al. (2017) Paclitaxel: What Has Been Done and the Challenges Remain Ahead. International Journal of Pharmaceutics, 526, 474-495. https://doi.org/10.1016/j.ijpharm.2017.05.016</mixed-citation></ref><ref id="hanspub.28370-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, B., Xue, A., Zhang, C., et al. (2016) Bile Salt Liposomes for En-hanced Lymphatic Transport and Oral Bioavailability of Paclitaxel. Pharmazie, 71, 320-326.</mixed-citation></ref><ref id="hanspub.28370-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">李科, 刘洁琼. 奈达铂联合紫杉醇脂质体治疗晚期食管癌的临床效果及安全性[J]. 肿瘤研究与临床, 2016, 28(11): 748-751.</mixed-citation></ref><ref id="hanspub.28370-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Chen, Q., Zhang, Q.Z., Liu, J., et al. (2003) Multi-Center Prospective Randomized Trial on Paclitaxel Liposome and Traditional Taxol in the Treatment of Breast Cancer and Non-Small-Cell Lung Cancer. Chinese Journal of Oncology, 25, 190-192.</mixed-citation></ref></ref-list></back></article>